AllSight
Companies · REPL · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc. (REPL)

Replimune Group, Inc. (REPL) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Replimune Group, Inc. (REPL) stock — financials & valuation

Key numbers for Replimune Group, Inc. (REPL): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 28/100 — a percentile rank of Replimune Group, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$1.3B
EV / EBITDA-4.0×
Return on equity-281.1%
ROIC-1025.2%
Debt / equity1.0×
Dividend yield0.0%

Is Replimune Group, Inc. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Replimune Group, Inc.’s own financial statements and shown as context, never as advice.

Aug 14, 2026Miss
The approval is old news; now the launch bill starts showing up
Aug 10, 2026
Replimune secures $140.5 million, but adds meaningful dilution
Aug 6, 2026
FDA approval clears the commercial path, but confirmatory risk remains
Related companies in Biological Products, (No Diagnostic Substances)
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact